ES2523194T3 - Anticuerpo monoclonal humano específico para cada tumor - Google Patents

Anticuerpo monoclonal humano específico para cada tumor Download PDF

Info

Publication number
ES2523194T3
ES2523194T3 ES08716518.9T ES08716518T ES2523194T3 ES 2523194 T3 ES2523194 T3 ES 2523194T3 ES 08716518 T ES08716518 T ES 08716518T ES 2523194 T3 ES2523194 T3 ES 2523194T3
Authority
ES
Spain
Prior art keywords
seq
tumor
monoclonal antibody
human monoclonal
specific human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08716518.9T
Other languages
English (en)
Inventor
Christoph Esslinger
Sandra Dietschy-Kuenzle
Irene Abela
Alfred Zippelius
Dirk Jaeger
Alexander Knuth
Roger M. D. Nitsch
Holger Moch
Norbert Goebels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich filed Critical Universitaet Zuerich
Application granted granted Critical
Publication of ES2523194T3 publication Critical patent/ES2523194T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Anticuerpo humano-murino quimérico, xenogénico, humanizado o humano, o fragmento de unión del mismo, que tiene la capacidad de reconocer el antígeno NY-ESO-1 asociado a tumor, que comprende en su región de cadena pesada variable las regiones determinantes de complementariedad CDR1 de ID SEC. n.º: 5, CDR2 de ID SEC n.º: 6, y CDR3 de ID SEC n.º: 7, y en su región de cadena ligera variable las regiones determinantes de complementariedad CDR1 de ID SEC n.º: 8, CDR2 de ID SEC n.º: 9 y CDR3 de ID SEC n.º: 10.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17

Claims (1)

  1. imagen1
ES08716518.9T 2007-03-13 2008-03-13 Anticuerpo monoclonal humano específico para cada tumor Active ES2523194T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07005180 2007-03-13
EP07005180 2007-03-13
PCT/EP2008/002021 WO2008110372A1 (en) 2007-03-13 2008-03-13 Monoclonal human tumor-specific antibody

Publications (1)

Publication Number Publication Date
ES2523194T3 true ES2523194T3 (es) 2014-11-21

Family

ID=39627674

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08716518.9T Active ES2523194T3 (es) 2007-03-13 2008-03-13 Anticuerpo monoclonal humano específico para cada tumor
ES12151047.3T Active ES2637214T3 (es) 2007-03-13 2008-03-13 Anticuerpo monoclonal humano específico para cada tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12151047.3T Active ES2637214T3 (es) 2007-03-13 2008-03-13 Anticuerpo monoclonal humano específico para cada tumor

Country Status (19)

Country Link
US (2) US8519106B2 (es)
EP (4) EP2457928B1 (es)
JP (2) JP2010520760A (es)
KR (1) KR101570702B1 (es)
CN (1) CN101652388B (es)
AU (1) AU2008225994B9 (es)
BR (1) BRPI0808940B8 (es)
CA (1) CA2680914C (es)
DK (1) DK2457928T3 (es)
ES (2) ES2523194T3 (es)
HU (1) HUE035762T2 (es)
IL (1) IL200615A (es)
MX (1) MX2009009926A (es)
NZ (1) NZ579520A (es)
PL (2) PL2457928T3 (es)
PT (1) PT2457928T (es)
RU (1) RU2488593C2 (es)
WO (2) WO2008110373A1 (es)
ZA (1) ZA200905874B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP2186827A1 (en) 2008-11-14 2010-05-19 HS LifeSciences Ltd. Surrogate marker directed cDNA cloning of selectively induced mRNAs
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
US8846872B2 (en) 2009-11-18 2014-09-30 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
SG10201501767VA (en) * 2010-03-10 2015-05-28 Genmab As Monoclonal antibodies against c-met
KR101614997B1 (ko) 2011-01-10 2016-04-22 씨티 아틀란틱 엘티디. 종양 관련 항원 결합 항체를 포함하는 조합 요법
BR112013033258B1 (pt) 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013098419A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of providing monoclonal auto-antibodies with desired specificity
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
AU2013266421B2 (en) * 2012-05-22 2017-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Murine anti-NY-ESO-1 T cell receptors
WO2015001047A1 (en) 2013-07-03 2015-01-08 Immunoqure Ag Method of providing anti-human cytokine antibodies for pharmaceutical use
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2019084538A1 (en) 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System TUMOR SPECIFIC ANTIBODIES, T CELL RECEPTORS AND METHODS OF IDENTIFICATION THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US6252052B1 (en) * 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6251603B1 (en) 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US20030236209A1 (en) 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
AU6266899A (en) * 1998-10-05 2000-04-26 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
DE19903525A1 (de) 1999-01-29 2000-08-03 Mewa Recycling Maschinen Und A Zerlegungseinrichtung für Altgeräte
EP1571211B1 (en) * 2002-11-22 2010-01-20 Chugai Seiyaku Kabushiki Kaisha Antibodies against lesional tissues
US7993864B2 (en) * 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
EP1608684A2 (en) * 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US9469678B2 (en) * 2003-03-04 2016-10-18 Ludwig Institute For Cancer Research NY-ESO-1 peptides which bind to class II molecules and uses thereof
US20080139464A1 (en) 2003-05-30 2008-06-12 Ludwig Institute Of Cancer Research Isolated Ny-Eso-1 Peptides Which Bind To Hla Class II Molecules And Uses Thereof
GB0409940D0 (en) 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US8399200B2 (en) 2004-05-26 2013-03-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Isolation of allergen-specific immunoglobulin genes from human B-cells from atopy sufferers
GB0412973D0 (en) * 2004-06-10 2004-07-14 Celltech R&D Ltd Identification of antibody producing cells
DE102006027224B3 (de) 2006-06-12 2008-01-03 Repower Systems Ag Windenergieanlage mit einer autarken Energieversorgung für eine Blattverstelleinrichtung
HUE033325T2 (en) 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use

Also Published As

Publication number Publication date
AU2008225994B2 (en) 2014-12-11
MX2009009926A (es) 2010-03-15
EP2125888A1 (en) 2009-12-02
DK2457928T3 (en) 2017-08-28
EP2457928A2 (en) 2012-05-30
CN101652388B (zh) 2013-12-25
WO2008110372A1 (en) 2008-09-18
EP2134746A1 (en) 2009-12-23
EP2134746B1 (en) 2014-08-06
ES2637214T3 (es) 2017-10-11
WO2008110373A1 (en) 2008-09-18
IL200615A (en) 2017-05-29
RU2009137784A (ru) 2011-04-20
BRPI0808940A8 (pt) 2019-02-05
BRPI0808940B8 (pt) 2021-05-25
PT2457928T (pt) 2017-08-17
AU2008225994A1 (en) 2008-09-18
HUE035762T2 (en) 2018-05-28
US20110123447A1 (en) 2011-05-26
RU2488593C2 (ru) 2013-07-27
JP2013223494A (ja) 2013-10-31
NZ579520A (en) 2012-06-29
JP5797687B2 (ja) 2015-10-21
KR20100014690A (ko) 2010-02-10
US8519106B2 (en) 2013-08-27
AU2008225994B9 (en) 2014-12-18
ZA200905874B (en) 2010-04-28
EP2457928A3 (en) 2012-06-20
PL2457928T3 (pl) 2017-10-31
BRPI0808940B1 (pt) 2019-10-08
US20100330075A1 (en) 2010-12-30
PL2134746T3 (pl) 2015-01-30
IL200615A0 (en) 2010-05-17
EP2125888B1 (en) 2015-12-02
EP3159355A1 (en) 2017-04-26
CN101652388A (zh) 2010-02-17
EP2457928B1 (en) 2017-05-10
CA2680914C (en) 2019-06-18
BRPI0808940A2 (pt) 2014-08-19
CA2680914A1 (en) 2008-09-18
JP2010520760A (ja) 2010-06-17
KR101570702B1 (ko) 2015-11-23

Similar Documents

Publication Publication Date Title
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
NO2017060I1 (no) sarilumab
EP3712178A4 (en) ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
CR9562A (es) Anticuerpos anti-cd40 humanizados y sus metodos de uso
PE20190737A1 (es) Anticuerpos anti-cd27
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
NZ611269A (en) Neutralizing anti-ccl20 antibodies
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
NZ621938A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
PE20110797A1 (es) Anticuerpos anti mn
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
NZ595235A (en) Compositions and methods for increasing muscle growth
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
AR105267A1 (es) Anticuerpos de unión a tau